

TARO PHARMACEUTICALS NORTH AMERICA INC.

BALANCE SHEETS

	March 31, 2019	March 31, 2018
	U.S. Dollars	
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	\$ 171,819	\$ 18,326,816
Short-term bank deposits	-	145,347,606
Marketable securities	-	58,591,895
Other receivables and prepaid expenses:		
Prepaid expenses	-	-
Intercompany balances	199,407,239	91,000,941
Other	-	2,224,908
TOTAL Other receivables and prepaid expenses	<u>199,407,239</u>	<u>93,225,849</u>
 TOTAL CURRENT ASSETS	 199,579,058	 315,492,166
LONG-TERM RECEIVABLES AND OTHER ASSETS	173,220,008	189,303,432
 GOODWILL	 -	 -
INTANGIBLE ASSETS AND DEFERRED COSTS, NET	-	-
TOTAL ASSETS	<u>\$ 372,799,066</u>	<u>\$ 504,795,598</u>
 LIABILITIES AND SHAREHOLDERS' EQUITY		
CURRENT LIABILITIES:		
Accounts payable:		
Trade payables	\$ -	\$ -
Other current liabilities:		
Intercompany balances	-	-
Accrued expenses	110,864	-
Other	-	-
TOTAL Other current liabilities	<u>110,864</u>	<u>-</u>
TOTAL CURRENT LIABILITIES	<u>110,864</u>	<u>-</u>
 SHAREHOLDERS' EQUITY	 <u>372,688,202</u>	 <u>504,795,598</u>
	<u>\$ 372,799,066</u>	<u>\$ 504,795,598</u>

Date of approval of the
financial statements

Mariano Balaguer
VP, Chief Financial Officer

TARO PHARMACEUTICALS NORTH AMERICA INC.

STATEMENTS OF INCOME

	For the year Ended March 31, 2019	For the year Ended March 31, 2018	For the year Ended March 31, 2017
	U.S. Dollars		
Sales	\$ -	\$ -	\$ 78,615,499
Cost of sales	-	-	21,051,304
Gross profit	-	-	57,564,195
Research and development	-	-	25,499,023
Selling and marketing expenses	-	-	1,029,215
General and administrative expenses	340,905	-	1,055,368
Operating income	(340,905)	-	29,980,590
Financing income (expenses), net	1,156,993	3,872,723	3,294,176
Other income (expense)	(8,348,412)	181,483,121	8,500,000
Income before taxes on income	(7,532,325)	185,355,844	41,774,766
Taxes on income	-	-	-
Net income for the period before subsidiaries and divid	(7,532,325)	185,355,844	41,774,766
Dividend income, net	-	-	-
Subsidiaries	-	-	-
Net income for the period	\$ (7,532,325)	\$ 185,355,844	\$ 41,774,766

TARO PHARMACEUTICALS NORTH AMERICA INC.

Changes in Shareholders' Equity

U.S. Dollars

	Number of Shares	Share Capital	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings	Total Tarco Shareholders' Equity	Noncontrolling Interest	Total Shareholders' Equity
Balance at March 31, 2016	3	3	3,511,728	-	282,808,400	286,320,131	-	286,320,131
Exercise of options and issuance of shares of ESPP	-	-	-	-	-	-	-	-
Comprehensive loss, net of tax	-	-	-	-	41,774,766	41,774,766	-	41,774,766
Net income	-	-	-	-	-	-	-	-
Balance at March 31, 2017	3	3	3,511,728	-	324,583,166	328,094,897	-	328,094,897
Exercise of options and issuance of shares of ESPP	-	-	(8,522,186)	-	-	(8,522,186)	-	(8,522,186)
Comprehensive income, net of tax	-	-	-	(132,957)	-	(132,957)	-	(132,957)
Net income	-	-	-	-	185,355,844	185,355,844	-	185,355,844
Balance at March 31, 2018	3	3	(5,010,458)	(132,957)	509,939,010	504,795,598	-	504,795,598
Adjustment to Opening RE balance	-	-	8,522,186	-	(8,522,186)	-	-	-
Dividends Paid	-	-	-	-	(124,708,028)	(124,708,028)	-	(124,708,028)
Comprehensive income, net of tax	-	-	-	132,957	-	132,957	-	132,957
Net income	-	-	-	-	(7,532,325)	(7,532,325)	-	(7,532,325)
Balance at March 31, 2019	3	3	3,511,728	-	369,176,471	372,688,202	-	372,688,202